Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.
PainReform Ltd (PRFX) is a clinical-stage pharmaceutical innovator developing advanced pain management solutions through therapeutic reformulation. This page aggregates official announcements, clinical trial updates, and strategic developments related to the company’s extended-release drug-delivery platform.
Investors and healthcare professionals will find timely updates on PRF-110’s progress through FDA pathways, postoperative analgesia research, and operational milestones. The curated news collection serves as a centralized resource for tracking the company’s unique approach to reducing opioid reliance via localized, sustained pain relief therapies.
Key content categories include clinical trial results, regulatory filings, partnership announcements, and scientific presentations. All materials are sourced from verified channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to PainReform’s latest developments in drug reformulation technology and its evolving position within the specialty pharmaceuticals sector.
PainReform (Nasdaq: PRFX) announced its expansion into the Smart Energy Management sector through the acquisition of DeepSolar, an AI-driven solar optimization software provider. The strategic move marks a significant shift from the company's pharmaceutical focus to tech-enabled markets.
DeepSolar's flagship product, MyDeepSolar, is an application that uses machine learning and predictive analytics to optimize solar energy systems for residential users. The platform offers real-time monitoring, yield forecasting, and performance optimization features to help homeowners maximize their solar investments.
According to Ehud Geller, Chairman and interim CEO, this expansion aligns with global energy trends and leverages a commercially scalable technology platform. The move comes amid increased M&A activity in the solar sector and growing government support through tax credits and smart grid infrastructure initiatives.
PainReform (PRFX) provided its 2024 year-end business update, highlighting two main developments: a setback in Phase 3 clinical trials for PRF-110 (post-operative pain relief drug) and the acquisition of DeepSolar, an AI-driven solar analytics platform.
Financial highlights for 2024:
- R&D expenses increased to $11.7M (vs $6.0M in 2023)
- G&A expenses decreased to $3.0M (vs $3.6M in 2023)
- Net loss widened to $14.6M (vs $9.3M in 2023)
- Working capital stood at $2.0M
The company raised $0.9M through its ATM program and believes it now exceeds Nasdaq's minimum shareholders' equity requirement of $2.5M following the DeepSolar acquisition. The company plans to address PRF-110's 24-hour data gap using advanced testing models while exploring strategic partnerships in the clean energy sector through DeepSolar.
PainReform (NASDAQ: PRFX) has completed its acquisition of DeepSolar, an AI-driven solar analytics platform, from BladeRanger The acquisition positions PainReform in the high-growth clean energy sector while maintaining its pharmaceutical focus.
DeepSolar's SaaS platform provides AI-powered solutions for solar energy asset management, promising to reduce maintenance costs by up to 30%. The platform integrates with SCADA systems for monitoring and predictive maintenance, targeting utility-scale operators, power producers, and residential users.
As consideration, BladeRanger received 178,769 ordinary shares (9.9% of PainReform) and 223,792 pre-funded warrants. Additional securities will be issued after the April 3, 2025 shareholders meeting, including milestone warrants and warrants-A/B, with a 9.99% ownership cap.
PainReform (PRFX) has executed a definitive agreement to acquire DeepSolar, an AI-driven solar analytics platform, from BladeRanger The acquisition, expected to close by February 2025, represents a strategic expansion while maintaining the company's commitment to drug delivery technologies.
DeepSolar's AI-powered platform optimizes solar energy assets, reducing operational costs by up to 30% and maximizing energy production. The platform serves both B2B (utility-scale operators) and B2C (residential) markets through its 'My DeepSolar' app.
As consideration, BladeRanger will receive 178,769 ordinary shares (9.9% of PainReform), plus various warrants totaling over 3 million potential shares. The agreement includes a 9.99% ownership cap and a 90-day restriction on new share issuances by PainReform. The company must register these securities with the SEC within 60 days of closing.
PainReform (Nasdaq: PRFX) provided an update on its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients. While the trial showed statistically significant superiority over placebo in pain reduction during the first 48 hours post-surgery, the company revealed that data from the final 24-hour period could not be clarified to meet the study's primary endpoint 72-hour requirement. As a result, the trial did not achieve its primary endpoint.
The company has initiated R&D activities to better understand and refine PRF-110's pharmaco-kinetics and pharmaco-dynamics based on study data. Management plans to use high-level, in-vitro models to address the 72-hour requirement issue before conducting additional clinical work. The company is also reviewing strategic options.
PainReform (Nasdaq: PRFX) announced partial topline data from its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients. The initial analysis shows statistically significant superiority over placebo in pain reduction during the first 48 hours post-surgery. However, data for the subsequent 24-hour period, important for the primary endpoint assessment, remains unclear due to data incoherence. The company is working with Lotus Clinical Research to resolve these data issues. PRF-110 is an oil-based, extended-release formulation of ropivacaine, designed to provide prolonged pain relief while reducing opioid dependency.
PainReform (Nasdaq: PRFX) has received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement. The company no longer meets the $2.5 million stockholders' equity threshold, the $35 million market value requirement, or the alternative $500,000 net income criteria. PainReform has until December 19, 2024, to submit a compliance plan to Nasdaq. If accepted, the company may receive an extension until May 3, 2025, to regain compliance. The notification does not immediately affect the listing or trading of shares on the Nasdaq Capital Market.
PainReform (Nasdaq: PRFX) has announced positive results regarding the compatibility of sutures in human clinical trials for its lead product, PRF-110. The company conducted in vitro studies to assess the impact of PRF-110 on both non-absorbable and resorbable sutures, specifically PROLENE™ and Vicryl™. The results showed that PRF-110 does not affect the mechanical properties of these sutures, including breaking force and elongation, after 14 days of exposure.
This finding is consistent with the phase III clinical results from the bunionectomy trial and supports the safety and efficacy of PRF-110 in post-surgical pain management. The compatibility of PRF-110 with surgical sutures is a significant advancement in post-operative care, as it allows for extended, non-opiate pain relief without compromising suture integrity.
PainReform (Nasdaq: PRFX), a clinical-stage pharmaceutical company, has announced agreements for the immediate exercise of outstanding warrants. These warrants, originally issued in December 2023 and April 2024, will purchase up to 989,300 ordinary shares at a reduced price of $1.60 per share, down from the original $4.80. The offering is expected to close around September 11, 2024.
In exchange for this exercise, PainReform will issue new unregistered warrants for up to 1,978,600 ordinary shares, exercisable immediately at $1.60 per share and expiring in five years. The company anticipates gross proceeds of approximately $1.58 million from this transaction, which will be used for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering.
PainReform (Nasdaq: PRFX) has successfully determined the optimal delivery method for PRF-110 in bunionectomy procedures, marking a significant milestone in advancing post-surgical pain management. Phase III evaluations have demonstrated PRF-110's superior physical properties, ensuring optimal coverage of cut nerve endings and traumatized tissue surfaces.
Key findings include effective wound coverage, competitive advantages over leading products, enhanced viscosity and uniformity, and precision delivery coverage. PRF-110 exhibited superior adhesion and location adherence compared to competitors, maintaining effectiveness even in the presence of physiological fluids. The product's optimal viscosity and uniformity facilitated ease of application and even distribution across the wound bed.
